Mechanisms involved in PGE(2)-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells

作者:Tveteraas Ingun Heiene*; Muller Kristin Meisdalen; Aasrum Monica; Odegard John; Dajani Olav; Guren Tormod; Sandnes Dagny; Christoffersen Thoralf
来源:Journal of Experimental & Clinical Cancer Research, 2012, 31: 72.
DOI:10.1186/1756-9966-31-72

摘要

Background: It is important to understand the mechanisms by which the cells integrate signals from different receptors. Several lines of evidence implicate epidermal growth factor (EGF) receptor (EGFR) in the pathophysiology of hepatocarcinomas. Data also suggest a role of prostaglandins in some of these tumours, through their receptors of the G protein-coupled receptor (GPCR) family. In this study we have investigated mechanisms of interaction between signalling from prostaglandin receptors and EGFR in hepatocarcinoma cells.
Methods: The rat hepatocarcinoma cell line MH1C1 and normal rat hepatocytes in primary culture were stimulated with EGF or prostaglandin E-2 (PGE(2)) and in some experiments also PGF(2 alpha). DNA synthesis was determined by incorporation of radiolabelled thymidine into DNA, phosphorylation of proteins in signalling pathways was assessed by Western blotting, mRNA expression of prostaglandin receptors was determined using qRT-PCR, accumulation of inositol phosphates was measured by incorporation of radiolabelled inositol, and cAMP was determined by radioimmunoassay.
Results: In the MH1C1 hepatocarcinoma cells, stimulation with PGE2 or PGF(2 alpha) caused phosphorylation of the EGFR, Akt, and ERK, which could be blocked by the EGFR tyrosine kinase inhibitor gefitinib. This did not occur in primary hepatocytes. qRT-PCR revealed expression of EP1, EP4, and FP receptor mRNA in MH1C1 cells. PGE(2) stimulated accumulation of inositol phosphates but not cAMP in these cells, suggesting signalling via PLC beta. While pretreatment with EP1 and EP4 receptor antagonists did not inhibit the effect of PGE(2), pretreatment with an FP receptor antagonist blocked the phosphorylation of EGFR, Akt and ERK. Further studies suggested that the PGE(2)-induced signal was mediated via Ca2+ release and not PKC activation, and that it proceeded through Src and shedding of membrane-bound EGFR ligand precursors by proteinases of the ADAM family.
Conclusion: The results indicate that in MH1C1 cells, unlike normal hepatocytes, PGE(2) activates the MEK/ERK and PI3K/Akt pathways by transactivation of the EGFR, thus diversifying the GPCR-mediated signal. The data also suggest that the underlying mechanisms in these cells involve FP receptors, PLC beta, Ca2+, Src, and proteinase-mediated release of membrane-associated EGFR ligand(s).